Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

21 Aug 2018 09:27

RNS Number : 4202Y
Canaccord Genuity Limited
21 August 2018
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Canaccord Genuity Limited

 

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Vernalis Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Connected party to the Offeree

 

(d) Date dealing undertaken:

20 August 2018

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

No

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

Ord 1p

Ord 1p

 

 

Purchase

Sale

100,000

100,000

 

6.06p

6.06p

 

6.06p

6.06p

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

NONE

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

NONE

 

Date of disclosure:

21 August 2018

Contact name:

Sam Holland

Telephone number:

020 7523 8337

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERZMGZRRMKGRZG
Date   Source Headline
25th Nov 201410:13 amRNSHolding(s) in Company
18th Nov 20147:00 amRNSChange of Year End & Commercial Business Update
6th Nov 20147:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
5th Nov 201412:15 pmRNSHolding(s) in Company
5th Nov 201412:07 pmRNSHolding(s) in Company
3rd Nov 20145:06 pmRNSHolding(s) in Company
31st Oct 20145:17 pmRNSHolding(s) in Company
31st Oct 20147:00 amRNSTotal Voting Rights
27th Oct 20147:00 amRNSCTI becomes worldwide licensee for tosedostat
14th Oct 20143:55 pmRNSTransactions of Directors
10th Oct 20147:00 amRNSVernalis opens US office and strengthens US team
9th Oct 20147:00 amRNSVernalis licenses V2006 to RedoxTherapies Inc
15th Sep 20147:00 amRNSFDA accepts TuzistraTM XR NDA for full review
5th Sep 201410:30 amRNSHolding(s) in Company
29th Aug 20144:00 pmRNSTotal Voting Rights
14th Aug 201410:59 amRNSHolding(s) in Company
5th Aug 20147:00 amRNSInterim results for six months ended 30 June 2014
4th Aug 20147:00 amRNSVernalis & Servier achieve 2 Research Milestones
31st Jul 20147:00 amRNSTotal Voting Rights
22nd Jul 20147:00 amRNS3rd Product in Cough Cold Pipeline Achieves POC
17th Jul 20147:00 amRNSNotice of Results for 6 Months Ended 30 June 2014
30th Jun 20147:15 amRNSTotal Voting Rights
30th Jun 20147:00 amRNSSubmission of TuzistraTM XR (CCP-01) NDA to FDA
19th Jun 20147:00 amRNSVernalis & Servier Achieve Research Milestone
30th May 20143:30 pmRNSTotal Voting Rights
23rd May 201411:48 amRNSResult of AGM
16th May 201410:47 amRNSHolding(s) in Company
6th May 20146:16 pmRNSBLOCK LISTING SIX MONTHLY RETURN
6th May 20144:31 pmRNSHolding(s) in Company
1st May 20143:15 pmRNSHolding(s) in Company
30th Apr 20149:00 amRNSTotal Voting Rights
29th Apr 20147:00 amRNS2nd Product in Cough Cold Pipeline Achieves POC
24th Apr 20147:00 amRNSPromising Results of Ph Ib/II POC Study in ADHD
22nd Apr 20147:01 amRNSVernalis Research wins Queens Award for Enterprise
15th Apr 20147:00 amRNSNotice of Annual Report and AGM
7th Apr 20145:41 pmRNSTransactions of Directors and Applicable Employee
1st Apr 20147:00 amRNSAnnouncement of Results for year ended 31 Dec 2013
31st Mar 20144:23 pmRNSTotal Voting Rights
27th Mar 20147:00 amRNSVernalis and Asahi Kasei Pharma Achieve Milestone
6th Mar 20147:00 amRNSAppointment of Joint Broker
5th Mar 20143:00 pmRNSNotice of Results
24th Feb 20147:00 amRNSVernalis Announces Successful Completion of Study
7th Feb 20147:00 amRNSAppointment of Nominated Adviser and Broker
29th Nov 20137:00 amRNSTotal Voting Rights
25th Nov 20137:00 amRNSVernalis Announces Successful Study with CCP-01
21st Nov 20135:05 pmRNSHolding(s) in Company
6th Nov 20137:00 amRNSBlock Listing Application
1st Oct 20134:40 pmRNSSecond Price Monitoring Extn
1st Oct 20134:35 pmRNSPrice Monitoring Extension
1st Oct 20137:00 amRNSVernalis enters into research collaboration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.